Abbott Presents New Data on Oncodetect® Whole-Genome Sequencing Test for Colorectal Cancer

Abbott presented new clinical data on its Oncodetect® whole-genome sequencing test for colorectal cancer at the European Society for Medical Oncology (ESMO). The test demonstrated a 30% absolute improvement in sensitivity, reflecting Abbott's commitment to advancing cancer diagnostics.